Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments. (9th February 2022)

• Record Type: Journal Article
• Authors: Kumar, Kartik; Daley, Charles L.; Griffith, David E.; Loebinger, Michael R.
• Is Part Of: European respiratory review. Volume 31:Number 163(2022)
• Publication Date: 2022-02-09
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiratory Tract Diseases; Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Electronic journals; Periodical; Periodicals; Periodicals; 616.2
• DOI: 10.1183/16000617.0212-2021
• Languages: English
• ISSNs: 0905-9180

Abstract

Nontuberculous mycobacterial pulmonary disease (NTM-PD) remains a challenging condition to diagnose and treat effectively. Treatment of NTM-PD is prolonged, frequently associated with adverse effects and has variable success. In this review, we consider the factors influencing clinicians when treating NTM-PD and discuss outcomes from key studies on the pharmacological management of Mycobacterium avium complex pulmonary disease and M. abscessus pulmonary disease. We highlight issues relating to treatment-related toxicity and provide an overview of repurposed and emerging therapies for NTM-PD. Despite advances in treatment regimens for nontuberculous mycobacterial pulmonary disease, significant challenges remain. Repurposed and emerging therapies may hold promise. https://bit.ly/3IBPh9q